Last reviewed · How we verify
NCT03568435
Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants
trial testing Non-Interventional in Kidney Cancer in 212 participants. Completed in 21 December 2020.
21 December 2020
Quick facts
| Lead sponsor | Bristol-Myers Squibb |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 212 |
| Start date | 14 February 2018 |
| Primary completion | 21 December 2020 |
| Estimated completion | 21 December 2020 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- Non-Interventional
Conditions studied
- Kidney Cancer — all drugs for Kidney Cancer →
- Renal Cancer — all drugs for Renal Cancer →
Sponsor
Bristol-Myers Squibb — full company profile →
Who can join
Eligibility, any sex, with Kidney Cancer or Renal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A non-interventional, medical record review of clinical data collected from Japanese participants with recurring kidney cancer
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Real-world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST-NIVO study): 36-month follow-up results of a clinical chart review.
Yonese J, Hinata N, Masui S, Nakai Y, et al · · 2023 · cited 1× · PMID 37248753 · DOI 10.1111/iju.15206
Verify or expand the search:
- PubMed search for NCT03568435
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Non-Interventional
Trials testing the same drug.
- NCT06412029 — Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practices · enrolling by invitation
- NCT05568459 — A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standa · active not recruiting
- NCT06527508 — Construct Validity and Intra-Observer Reliability of the SDQ · completed
- NCT05919511 — Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease · recruiting
- NCT05510908 — Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC · completed
Other recruiting trials for Kidney Cancer
Currently open trials in the same condition.
- NCT07401875 — A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) · Phase 1 · recruiting
- NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
- NCT06964958 — 177LuPSMA in Renal Cell Carcinoma · Phase 2 · active not recruiting
Other Bristol-Myers Squibb trials
Trials by the same sponsor.
- NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
- NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
- NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
- NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
- NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03568435 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
- Last refreshed: 20 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03568435.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing